Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

REGENXBIO Inc. - Common Stock (NQ:RGNX)

9.130 +0.040 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
What 5 Analyst Ratings Have To Say About Regenxbio
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
 
Via Benzinga
Recap: Regenxbio Q3 Earnings
Regenxbio (NASDAQ:RGNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Within the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings: 
Via Benzinga
4 Analysts Have This to Say About Regenxbio
  Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Regenxbio's Earnings Outlook
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
B of A Securities cut Alphabet Inc. (NASDAQ: GOOGL) price target from $125 to $114. Alphabet shares rose 1.9% to $100.50 in pre-market trading. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Expert Ratings for Regenxbio
Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter: 
Via Benzinga
Expert Ratings for Regenxbio
Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Regenxbio's Earnings Outlook
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
5 Small-Cap S&P Stocks To Buy With The Most Upside
The S&P 500 is one of the most popular U.S. stock indices and is often what investors and experts are referring to when they mention the "stock market." However, there's more to the market than... 
Via Benzinga
Regenxbio's Return On Capital Employed Overview
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million. 
Via Benzinga
Expert Ratings for Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
57 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
Regenxbio's Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65... 
Via Benzinga
Expert Ratings For Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.